Riskpilot← Back to searchSign inGet full accessRecipharm Venture Fund AB
ABActiveOrg 5566662697StockholmOther activities auxiliary to financial services, except insurance and pension funding · NACE 6619Est. 20040 employees
Revenue 2024
SEK 0
EBITDA margin
—
+89% vs 2023
Equity ratio
99.9%
Financial strength
Net profit 2024
SEK 607K
-10% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -149K | +89% |
| Net profit | SEK 607K | -10% |
| Total assets | SEK 28,2M | +2% |
| Equity | SEK 28,1M | +2% |
| Employees | 0 | — |
Legal name
Recipharm Venture Fund AB
Org number
5566662697
Legal form
Aktiebolag
NACE code
6619 · Other activities auxiliary to financial services, except insurance and pension funding
Founded
14 september 2004
Share capital
SEK 400 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Bolaget skall bedriva utveckling, tillverkning och försäljning av läkemedel, naturläkemedel, kosttillskott, medicinska hjälpmedel och därmed förenlig verksamhet'; bidra till utveckling av nya läkemedel och till att sälja utvecklingstjänster inom koncernen' samt styra och utveckla immateriella, finansiella och liknande rättigheter inom denna bransch och närliggande branscher.
Address
Stockholm
Email
legal@recipharm.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 13 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −155 | −213 | −330 | −1 299 | −149 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −155 | −213 | −330 | −1 299 | −149 |
| Net financials | 3 147 | 28 083 | −11 953 | 411 | 608 |
| Profit before tax | −49 | −35 | −6 281 | 738 | 607 |
| Tax | −0 | −0 | 67 | −67 | −0 |
| Net profit | −49 | −35 | −6 214 | 671 | 607 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 47 743 | 60 980 | 26 867 | 27 531 | 28 170 |
| Equity | 33 110 | 33 075 | 26 861 | 27 532 | 28 139 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 14 633 | 27 905 | 6 | 0 | 32 |
| Total debt | 14 633 | 27 905 | 6 | — | 32 |
EBITDA margin
-14900000.0%
This company
15.8%
Market median
-94303897% vs market
20202024
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
2.2%
This company
18.4%
Market median
-88% vs market
20202024
Net profit margin
60700000.0%
This company
8.1%
Market median
+749382616% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
CS Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
BM Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
JR Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2026 | |
| Chairman | 2026 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2024 | |
| Former (8) | ||
| Deputy Board Member | 2022 – 2023 | |
| Board of Directors | 2024 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2024 – 2024 | |
| Board of Directors | 2022 – 2023 | |
| Deputy Board Member | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Roar Holdco AB
Recipharm Venture Fund AB Board members of Recipharm Venture Fund AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl-Johan Spak | Chief Executive Officer | 0 companies |
| Bernard Michel Noel Pluta | Chief Executive Officer | 0 companies |
| Jennifer Rock Baley | Chief Auditor | 0 companies |
| Barbro Maria Fredrika Riccius | Board of Directors | 0 companies |
| Carl Olof Torkel Gren | Deputy Board Member | 0 companies |
| Lars Jörgen Rahm | Board of Directors | 0 companies |
| Andrew Robert Anthony Dawson | Chairman | 0 companies |
| Johanna Mirjam Kvist | Board of Directors | 0 companies |
| Nese Akay Kemahli | Board of Directors | 0 companies |
| Thomas Bengt Eldered | Board of Directors | 0 companies |
| Rohit Kishore Sidhwani | Deputy Board Member | 0 companies |
| Lisa Lodge | Board of Directors | 0 companies |
| Valur Sveinbjörnsson | Board of Directors | 0 companies |
| Dimitri Gold | Deputy Board Member | 0 companies |
| Thord Herman Emil Hargestam | Deputy Board Member | 0 companies |